Objective: To determine the prevalence of mucosal alterations and oral lesions diagnosed at the School of Dentistry, Federal University of Amazonas, Manaus-Brazil. Materials and methods: Cross-sectional, descriptive and retrospective study, which analyzed the medical records of patients over 18 years of age from 2010 to 2013. Data were collected related to presence of soft tissue alterations, with emphasis on white-colored lesions, as well as variables such as age, gender, use of medications, systemic diseases and deleterious habits. The data were submitted to descriptive analysis and presented by average and standard deviation by means of tables. Results: 82 medical records were included, with prevalence of the female (60.98%) and mean age of 43.3 years. A total of 307 oral mucosa alterations were found and among these 27.69% consisted of white-colored lesions. Fordyce granules (35.37%)...

Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with acute, lymphoma, and chronic subtypes with relapsed/refractory, aggressive disease in the US, Europe, and Latin America. With stratification by subtype, patients were randomized 2:1 to intravenous mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter (n=47) or investigator's choice of chemotherapy (n=24). The primary end point was confirmed overall response rate (cORR) confirmed on a subsequent assessment at 8 weeks by blinded independent review. ORR was 11% (95%CI: 4-23%) and 0% (95%CI: 0-14%) in the mogamulizumab and chemotherapy arms, respectively. Best response was 28% an...